Hiroshi Kotani

1.3k total citations
34 papers, 770 citations indexed

About

Hiroshi Kotani is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Hiroshi Kotani has authored 34 papers receiving a total of 770 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 20 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Hiroshi Kotani's work include CAR-T cell therapy research (14 papers), Viral Infectious Diseases and Gene Expression in Insects (6 papers) and Melanoma and MAPK Pathways (5 papers). Hiroshi Kotani is often cited by papers focused on CAR-T cell therapy research (14 papers), Viral Infectious Diseases and Gene Expression in Insects (6 papers) and Melanoma and MAPK Pathways (5 papers). Hiroshi Kotani collaborates with scholars based in Japan, United States and Malaysia. Hiroshi Kotani's co-authors include Seiji Yano, Hiromichi Ebi, Anthony C. Faber, Marco L. Davila, Justin C. Boucher, Gongbo Li, Mari Mino–Kenudson, Hidenori Kitai, Youngchul Song and Yuta Adachi and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Hiroshi Kotani

29 papers receiving 760 citations

Peers

Hiroshi Kotani
Zijie Feng China
Natalia Di Ianni Italy
Victoria Casado‐Medrano United States
Nicholas G. Minutolo United States
Birgitta E. Michels Germany
Federica Ruffini Italy
R. Sonali Majumdar United States
Theresa A. Proia United States
Han Dong United States
Jessica M. Posada United States
Zijie Feng China
Hiroshi Kotani
Citations per year, relative to Hiroshi Kotani Hiroshi Kotani (= 1×) peers Zijie Feng

Countries citing papers authored by Hiroshi Kotani

Since Specialization
Citations

This map shows the geographic impact of Hiroshi Kotani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroshi Kotani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroshi Kotani more than expected).

Fields of papers citing papers by Hiroshi Kotani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroshi Kotani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroshi Kotani. The network helps show where Hiroshi Kotani may publish in the future.

Co-authorship network of co-authors of Hiroshi Kotani

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroshi Kotani. A scholar is included among the top collaborators of Hiroshi Kotani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroshi Kotani. Hiroshi Kotani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Zhang, Yongliang, Muhammad Junaid Tariq, Eduardo Cortes Gomez, et al.. (2025). IFN-γ–driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapy. Journal of Clinical Investigation. 136(1).
3.
Sato, Shigeki, Hiroshi Kotani, Kaname Yamashita, et al.. (2024). Effectiveness of Additional Immunosuppressive Drugs for Corticosteroid-refractory Immune Checkpoint Inhibitor-induced Myocarditis: Two Case Reports. Internal Medicine. 64(8). 1205–1210. 2 indexed citations
4.
Fukuda, Koji, Shinji Takeuchi, Shigeki Nanjo, et al.. (2024). Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations. Cell Reports Medicine. 5(6). 101578–101578. 11 indexed citations
5.
Nishiyama, Akihiro, Shigeki Sato, Hiroshi Kotani, et al.. (2024). Pembrolizumab efficacy in a tumor mutation burden‐high glioblastoma patient: A case study and implications for precision oncology. Cancer Science. 116(1). 271–276.
6.
Roselli, Emiliano, Justin C. Boucher, Gongbo Li, et al.. (2021). 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. Journal for ImmunoTherapy of Cancer. 9(10). e003354–e003354. 85 indexed citations
7.
Boucher, Justin C., Gongbo Li, Hiroshi Kotani, et al.. (2020). CD28 Costimulatory Domain–Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function. Cancer Immunology Research. 9(1). 62–74. 48 indexed citations
8.
Namkoong, Ho, Katsunori Masaki, Yutaka Kurebayashi, et al.. (2020). IL-6 and G-CSF production resulting from lung cancer in an HIV patient. IDCases. 19. e00693–e00693. 3 indexed citations
9.
Namkoong, Ho, et al.. (2020). Hidden disseminated extracutaneous AIDS-related Kaposi sarcoma. IDCases. 19. e00716–e00716. 2 indexed citations
10.
Jain, Michael D., Meghan Menges, Rawan Faramand, et al.. (2019). Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in Lymphoma. Blood. 134(Supplement_1). 2885–2885. 9 indexed citations
11.
Faramand, Rawan, Hiroshi Kotani, Dylan Morrissey, et al.. (2019). Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements. Biology of Blood and Marrow Transplantation. 25(3). S408–S409. 5 indexed citations
12.
Li, Gongbo, Justin C. Boucher, Hiroshi Kotani, et al.. (2018). 4-1BB enhancement of CAR T function requires NF-κB and TRAFs. JCI Insight. 3(18). 104 indexed citations
13.
Tanimoto, Azusa, Shinji Takeuchi, Hiroshi Kotani, et al.. (2018). Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report. BMC Pulmonary Medicine. 18(1). 193–193. 11 indexed citations
14.
Kotani, Hiroshi, Yuta Adachi, Hidenori Kitai, et al.. (2018). Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. Oncogene. 37(13). 1775–1787. 24 indexed citations
15.
Kotani, Hiroshi, Tatsuki Kurokawa, Masayuki Mori, et al.. (2017). C-terminal splice variants of P/Q-type Ca2+ channel CaV2.1 α1 subunits are differentially regulated by Rab3-interacting molecule proteins. Journal of Biological Chemistry. 292(22). 9365–9381. 23 indexed citations
16.
Kitai, Hidenori, Hiromichi Ebi, Shuta Tomida, et al.. (2016). Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS -Mutant Lung Cancer. Cancer Discovery. 6(7). 754–769. 108 indexed citations
17.
Tanimoto, Azusa, Shinji Takeuchi, Hiroshi Yaegashi, et al.. (2016). Recurrence of renal cell carcinoma diagnosed using contralateral adrenal biopsy with endoscopic ultrasound-guided fine-needle aspiration. Molecular and Clinical Oncology. 4(4). 537–540. 1 indexed citations
18.
Kotani, Hiroshi, Hiromichi Ebi, Hidenori Kitai, et al.. (2015). Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression. Oncogene. 35(27). 3587–3597. 32 indexed citations
19.
Ebi, Hiromichi, Carlotta Costa, Anthony C. Faber, et al.. (2013). PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proceedings of the National Academy of Sciences. 110(52). 21124–21129. 174 indexed citations
20.
Kotani, Hiroshi, et al.. (1981). HUMAN T-CELLS HAVING RECEPTORS FOR AUTOLOGOUS ERYTHROCYTES ARE SUPPRESSOR PRECURSORS AND THOSE NOT HAVING THE RECEPTORS ARE AMPLIFIER CELLS. 40(3). 1140. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zijie Feng Breakdown of academic impact, for papers by Natalia Di Ianni Breakdown of academic impact, for papers by Victoria Casado‐Medrano Breakdown of academic impact, for papers by Nicholas G. Minutolo Breakdown of academic impact, for papers by Birgitta E. Michels Breakdown of academic impact, for papers by Federica Ruffini Breakdown of academic impact, for papers by R. Sonali Majumdar Breakdown of academic impact, for papers by Theresa A. Proia Breakdown of academic impact, for papers by Han Dong Breakdown of academic impact, for papers by Jessica M. Posada
Rankless by CCL
2026